Press Releases

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results
May 9, 2024
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering
April 18, 2024
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co.
March 6, 2024
Displaying 1 - 10 of 14
Print Page
RSS Feeds
Email Alerts
Contact IR